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RESUMO – A síndrome de Kounis caracteriza-se por um síndrome coronário agudo devido a vasoespasmo arterial que ocorre 
em reacções alérgicas imediatas ou na urticária crónica espontânea. Recentemente foi reportado a nível da vasculatura cerebral.
Apresentamos três pacientes observadas entre Janeiro de 2016 e Dezembro de 2018 com acidente vascular cerebral agudo ou 
transitório durante exacerbações de urticária crónica espontânea, incluindo uma doente com episódios neurológicos recorrentes 
coincidentes com as crises de urticária. Foram detectadas alterações isquémicas cerebrais em duas doentes, mas não foram encon-
trados factores de risco cardiovascular ou anormalidades da coagulação que explicassem os sintomas neurológicos. 
A urticária crónica espontânea, através da activação e libertação de mediadores por parte dos mastócitos, poderá induzir dano a 
nível da vasculatura cerebral. Os autores enfatizam esta possível associação e a necessidade do controlo das crises de urticária de 
forma a prevenir manifestações de dano vascular.    
PALAVRAS-CHAVE – Doença da Artéria Coronária/complicações; Hipersensibilidade;Lesões Cerebrais; Urticária. 
Brain Injury Associated with Chronic Spontaneous 
Urticaria: a Kounis-Like Syndrome?   
ABSTRACT – ‘Kounis Syndrome’ is an acute coronary artery event due to an artery spasm occurring during immediate hypersensi-
tivity reactions or chronic spontaneous urticaria. Recently it has been reported in other systems, including the cerebral vasculature. 
We present a case series of three patients observed between January 2016 and December 2018 with acute and transient brain 
injury associated with concomitant exacerbation of chronic spontaneous urticaria, including one patient with multiple recurrences 
of neurologic symptoms during exacerbations of urticaria. Minor imaging defects were observed in two patients, but there were no 
apparent vascular risk factors or coagulation abnormalities that might explain neurologic symptoms.
Chronic spontaneous urticaria, through activation of mast cells and mediator release, seems capable of inducing cerebral arterial 
aggression. The authors want to call the attention to this possible association, reinforcing the need to keep urticaria under control 
to prevent neurological manifestations.  
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INTRODUCTION
"Kounis syndrome" (KS), described in 1991 as the syn-
drome of allergic angina, is defined as the concomitant 
occurrence of an immediate allergic or hypersensitivity reac-
tion and acute coronary events in patients with normal co-
ronary arteries with or without predisposing factors, and in 
patients with stent thrombosis (type I, II or III variants, res-
pectively).1 Mast cell (MC) activation and release of their 
mediators during anaphylaxis or the hypersensitivity reac-
tion are the key events underlying coronary artery spasm.2 
There are several factors and diseases that may induce KS, 
including venoms, food allergens, drugs, stings by ants and 
jellyfishes, various conditions (angioedema/urticaria, asth-
ma, exercise induced allergy, mastocytosis and serum sick-
ness) and a variety of environmental exposures (poison ivy, 
latex contact, limpet ingestion).3 In recent years, KS has also 
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been associated with exacerbation of physical4-6 or chronic 
spontaneous urticaria7 (CSU). In CSU, type I and IIb autoim-
mune mechanisms (respectively with cross-linking of auto-
reactive IgE by autoallergens or with IgG autoantibodies 
binding to FcHRI or IgE), cause activation and degranulation 
of skin mast cells and basophils.8 Both preformed granule-
-associated mediators such as histamine, neutral proteases, 
cytokines, chemokines and proteoglycans and the lipid me-
diators rapidly synthesised from endogenous arachidonic 
acid, such as prostaglandin D2, leukotriene B4 and LTC4, 
have been associated with arterial spasm or rupture of athe-
romatous plaques in the heart.2,3 
More rarely, Kounis-like syndromes had been reported in 
other systems, including one case of transient cerebral vasos-
pasm occurring in chronic urticaria.9 
CLINICAL CASES
We report three patients from our urticaria center obser-
ved between January 2016 and December 2018 who de-
veloped acute and transient cerebral injury coincident with 
CSU exacerbations without any other apparent cause, con-
comitant disease, previous vascular risk or coagulation ab-
normalities that might explain neurologic symptoms. Apart 
from brain computed tomography (CT) and/or magnetic 
resonance imaging (MRI) performed by all patients at the 
emergency and after neurologic recovery, the following tests 
performed immediately after the acute episode were nor-
mal: electroencephalography (EEG) (except case 3), carotid 
Doppler ultrasound, echocardiogram and blood tests, that 
included complete blood count and differential, basic meta-
bolic panel, thyroid hormones, coagulation parameters and 
tests for thrombophilia, homocysteine, antinuclear, anti-ds-
-DNA and ANCA antibodies, anti-neuronal antibodies (Hu, 
Ri, Yo, amphiphysin, recoverin, titin, Ma2, CV2 and Sox1), 
complement factors, immunoglobulins, serum protein elec-
trophoresis, serologies for HIV, syphilis, Borrelia burgdorfe-
ri, Toxoplasma gondii, Rubella, Epstein-Barr, Herpes simplex 
and Cytomegalovirus. 
Case 1: 43-year-old woman, 13-week history of CSU 
under 2-fold dose of H1-antihistamines, referred three times 
to the emergency room: first due to intense headache, pho-
tophobia and diplopia; second (six days later) because of 
dysmetria and left perioral paraesthesia; third (one month 
later) with nausea, dizziness and ataxia. All these episodes 
were coincident with CSU exacerbations with exuberant la-
bial angioedema. Between episodes, the patient received 
oral corticotherapy, prescribed in emergency room, with re-
bound when withdrawal was attempted. Brain CT and MRI 
performed in the last episode were consistent with an acute 
small left cerebellar infarction. Conservative management 
was decided and the patient started acetylsalicylic acid, phy-
sical rehabilitation and 4-fold dose of H1-antihistamine with 
stabilization of CSU and improvement of neurologic symp-
toms, although there is persistence of vertigo during mobili-
zation at one year follow-up. 
Case 2: 44-year-old woman, with a 6-month diagnosis 
of CSU, presented with altered mental status and right body 
paresis consistent with moderate faciobrachiocrural motor 
hemisyndrome during a CSU exacerbation which started 3 
hours prior to admission. The patient had stopped H1-an-
tihistamines one month before due to apparent CSU con-
trol. Brain TC and MRI showed an acute stroke involving the 
posterior left lenticular nucleus. CT angiography demonstra-
ted increased regional blood flow compatible with a stroke 
in early reperfusion phase. The patient was admitted to the 
neurology service for stroke workup and poststroke care with 
physical and occupational therapy. For CSU the patient star-
ted 4-fold H1-antihistamines with partial control and one 
month later omalizumab with excellent response. She had 
a dramatic improvement relative to her initial presentation. 
At one year follow-up, she persists with a subtle decrease on 
right muscle strength. 
Case 3: 47-year-old woman, with CSU for 8 months 
under 1-fold dose of H1-antihistamines with partial control, 
presented with garbled speech, dizziness and transient right 
upper limb monoparesis that lasted 30 minutes during an 
angioedema episode. Brain CT performed in the emergen-
cy room and later MRI did not show abnormalities. She was 
diagnosed with a transient ischemic attack and started ace-
tylsalicylic acid. When questioned, the patient remembers 
previous transient numbness and confusion during exube-
rant CSU episodes. For CSU, ciclosporine was administered 
for 6 months and later changed to omalizumab, both with 
good response. No more neurologic alterations were obser-
ved in 18 month follow-up.  
DISCUSSION
All these cases occurred in female patients without vas-
cular risk factors or family history of brain injury. They had 
previous history of CSU and referred an acute exacerbation 
before or concomitant with the neurologic episode. Clinical 
symptoms, absence of abnormalities in all complementary 
exams and recurrence of neurologic symptoms with simul-
taneous CSU exacerbations (particularly in case 1) support 
the hypothesis that the acute release of MC mediators may 
be responsible for arterial vasospasm affecting the central 
nervous system. Although we cannot definitively prove the 
sequence of events, because serial evaluation of the vascular 
brain system and quantification of any of the MC mediators 
(eg. tryptase levels) in the acute episode were not performed, 
an association between CSU exacerbations and acute/tran-
sient vascular brain damage seems probable. 
This relationship could be explained by MC activation du-
ring exacerbation of urticaria. MC are recognized as resident 
cells within the cerebral vasculature and can affect it either di-
rectly through their mediators (histamine, tryptase, chymase, 
chemotactic factors and inflammatory cytokines) or indirectly 
due to interaction with inflammatory cells. MC have been as-
sociated with blood–brain barrier damage, brain oedema, 
reduction of cerebral blood flow and induction of cerebral 
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artery spasm.10,11 There is experimental and clinical evidence 
that anaphylactic shock decreases cerebral blood flow more 
than what would be expected from severe arterial hypoten-
sion12 and this has been attributed to the early and direct 
action of MC mediators on cerebral vessels after massive re-
lease of MC mediators. So, it is anticipated that the primary 
target of MC mediators is the arterial vasculature and brain 
injury may, therefore, represent a manifestation of a complex 
pan-arterial hypersensitivity-associated disorder.13 The exact 
mechanisms of action are not well understood. For instance, 
histamine has been associated with ischemia-induced neuro-
nal death in rats and increased brain-blood barrier permea-
bility,14 but in recent studies, it appears to have a protective 
effect on cerebral ischemic injury.15 Further studies are neces-
sary to elucidate these interactions and their role in stroke.
These findings suggest that CSU, through MC activation 
and mediator release, may induce cerebral arterial damage, 
similar to the transient coronary symptoms reported parti-
cularly during cold-induced urticaria episodes. Tryptase de-
terminations should be available in emergency services in 
order to confirm/diagnose this relationship when suspected, 
although they are not routinely performed during acute epi-
sodes. The authors want to call the attention to the possibility 
that CSU may explain transient neurological manifestations 
and emphasize the need to keep CSU under control to pre-
vent these neurological symptoms.
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